447 related articles for article (PubMed ID: 19959518)
21. New contrast agents for imaging the liver.
Helmberger T; Semelka RC
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
24. Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography--initial experience.
Yeh BM; Breiman RS; Taouli B; Qayyum A; Roberts JP; Coakley FV
Radiology; 2004 Mar; 230(3):645-51. PubMed ID: 14990830
[TBL] [Abstract][Full Text] [Related]
25. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
26. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky NM; Weinreb JC
Magn Reson Q; 1992 Sep; 8(3):156-68. PubMed ID: 1390058
[TBL] [Abstract][Full Text] [Related]
27. Primovist, Eovist: what to expect?
Van Beers BE; Pastor CM; Hussain HK
J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
[TBL] [Abstract][Full Text] [Related]
29. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
31. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications.
Lee NK; Kim S; Lee JW; Lee SH; Kang DH; Kim GH; Seo HI
Radiographics; 2009 Oct; 29(6):1707-24. PubMed ID: 19959517
[TBL] [Abstract][Full Text] [Related]
32. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
33. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
[TBL] [Abstract][Full Text] [Related]
34. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
35. MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity.
Takao H; Akai H; Tajima T; Kiryu S; Watanabe Y; Imamura H; Akahane M; Yoshioka N; Kokudo N; Ohtomo K
Eur J Radiol; 2011 Feb; 77(2):325-9. PubMed ID: 19726150
[TBL] [Abstract][Full Text] [Related]
36. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
37. Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging.
Kim H; Kim MJ; Park MS; Cha SW; Lim JS; Yoo HS; Kim KW
J Comput Assist Tomogr; 2010 Jan; 34(1):113-20. PubMed ID: 20118733
[TBL] [Abstract][Full Text] [Related]
38. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.
Tamada T; Ito K; Sone T; Kanki A; Sato T; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e207-11. PubMed ID: 20869827
[TBL] [Abstract][Full Text] [Related]
39. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
Homayoon B; Diwakar H; Strovski E; Bakshi D; Harris AC; Thoeni RF; Chang SD
Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
[TBL] [Abstract][Full Text] [Related]
40. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
